InflaRx $75 million follow-on offering
We advised the underwriters on the equity offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Ayala Pharmaceuticals $25 million private placement
We advised the placement agent on the private placement of stock and warrants
Applied Genetic Technologies follow-on offering
We advised the underwriters on the equity offering
American Well $356.8 million secondary offering
We advised Amwell on the stock offering
Northern Genesis Acquisition II $414 million IPO
We advised the underwriters on the SPAC IPO and NYSE listing
Consonance-HFW Acquisition $80 million IPO
Davis Polk advised the sole book-running manager in connection with the $80 million initial public offering of 8,000,000 units of Consonance-HFW Acquisition Corp. Each unit consists of…
BioNTech $500 million SEC-registered at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by BioNTech SE of its ordinary shares represented by American depositary shares for up to an…
Gatos Silver $150 million IPO
Davis Polk advised Gatos Silver, Inc. on its SEC-registered initial public offering of 21,430,000 common shares for total gross proceeds of approximately $150 million. In addition, Gatos…
ADC Therapeutics $204 million SEC-registered offering
Davis Polk advised ADC Therapeutics SA on its SEC-registered offering of 6,000,000 common shares for total gross proceeds of $204 million. ADC Therapeutics is listed on the New York…
Chewy $282 million public offering
Davis Polk advised the underwriter in connection with a $282 million public offering of 5,100,000 shares of Class A common stock of Chewy, Inc. In addition, the underwriter has an…